mage3 peptide-pulsed dendritic cell-derived exosomes

MAGE3 peptide-pulsed dendritic cell-derived exosomes (Dex) is an experimental autologous cancer vaccine and biologic. It consists of nanomeric vesicles (50–90 nm) purified from a patient's own monocyte-derived dendritic cell (DC) cultures, which are then loaded with MAGE3 tumor-associated peptide antigens (including MHC class I and MHC class II epitopes). These exosomes carry functional MHC/peptide complexes that are transferred to endogenous dendritic cells to prime MAGE3-specific CD4+ and CD8+ T cell immune responses. Additionally, the therapy promotes NK cell activation via NKG2D and IL-15Rα pathways. Developed by Institut Curie and Anosys, this immunotherapy has been investigated in Phase I clinical trials for the treatment of MAGE3-expressing metastatic melanoma and non-small cell lung cancer (NSCLC).

Other names

MAGE3-pulsed DexMAGE-3-pulsed DexMAGE 3-pulsed DexMAGE3-pulsed dendritic cell-derived exosomesMAGE-3-pulsed dendritic cell-derived exosomesMAGE 3-pulsed dendritic cell-derived exosomesautologous dendritic cell-derived exosomes pulsed with MAGE3 peptides